New smartphone app may help patients take better care of their vision at home

NewsGuard 100/100 Score

Patients with age-related macular degeneration or diabetic retinopathy who used a mobile application to test their vision at home got comparable results to in-office vision testing, according to research presented today at AAO 2017, the 121st Annual Meeting of the American Academy of Ophthalmology. The findings suggest that the smartphone app may help patients take better care of their vision.

Ophthalmologists – physicians who specialize in medical and surgical eye care – have effective treatment options for AMD and diabetic retinopathy that slow or prevent vision loss. But treatment is most effective when it's given at the earliest signs of disease.

That's why ophthalmologists often ask their patients to check their vision at home with a test called the Amsler grid. It is a simple square on a sheet of paper containing a grid pattern and a dot in the middle. When used correctly, it can show problem spots in a patient's field of vision. However, research shows that patients often fail to use the Amsler grid between office visits, and patients find it difficult to use effectively.

The app, known as Checkup, is designed to engage patients with their health care. Patients use it to assess their vision as often as their ophthalmologist prescribes. The voice-activated app also sends reminders to a patient's device if they forget to test on schedule. Results of the test are sent in real time to a secure cloud-based data warehouse. The ophthalmologist can view the results, and contact the patient if they detect a deterioration in their vision.

Researchers at Northern California Retina Vitreous Associates in Mountain View, Calif., wanted to find out if a smartphone app can monitor patients' vision at home as accurately as vision testing in the ophthalmologist's office, so they asked 27 patients with either AMD or diabetic retinopathy to use the app for two months.

Patients tested their vision at home using the app and were then re-tested in the office. There was strong agreement between the Checkup app and the in-office tests for both visual acuity and Amsler grid testing. Every patient reported that it was easy to use.

Linda Redington, 57, and her 83-year-old mother, Ethel Redington, were part of the study. They both have AMD. They said it was easy to set up on their phones and easy to use. Both Linda and Ethel tested their vision with a basic visual acuity test and the Amsler grid test.

"I never missed a day," Linda Redington said. "It was easy and it didn't take a big chunk out of the day. It took just five minutes."

She says that the Amsler grid test on the app was easier to use than the a static, black dot on a piece of paper. Instead of wieding a pen and piece of paper, the app serves up a red, flashing light that she simply taps with her finger.

"We're excited about the potential of this technology to improve patient care," said lead researcher, Rahul N. Khurana, M.D. "More and larger studies are required to make sure it works as well as our small study showed. But we found that it encouraged patients to take a more active role in their care, and they found it easy to use."

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New research pinpoints key pathways in prostate cancer's vulnerability to ferroptosis